The US Drug Supply Chain: Safety Must be Paramount - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The US Drug Supply Chain: Safety Must be Paramount
Holding product and supply-chain security to the highest standards is crucial for the future.

Pharmaceutical Technology
Volume 35, Issue 1, pp. 97-98

Additional monitoring

As drug products are shipped to wholesalers, pharmacies or other intermediaries, the pharmaceutical industry uses multiple controls to mitigate the risk of contamination or adulteration. Careful planning of drug shipments, along with strict supply-chain custody and controls, are part of the logistical operations that provide accountability and oversight of products moving through the supply channels. These judicious controls enable manufacturers to determine any deviation from the predetermined agenda for shipment and custody.

Overlaying these industry efforts is an extra level of protection provided by the FDA through its oversight of raw materials and finished dose suppliers. Although unfortunate events undoubtedly will occur from time to time, FDA's high standards for API and prescription drug production are the most rigorous in the world.

The pharmaceutical industry, including GPhA members, strongly supports FDA's vision of a safe and secure prescription drug supply chain based on transparency and accountability by all persons who handle prescription medicines throughout the supply chain. As the industry continues to expand its global footprint, no shortcuts in drug-product quality or supply-chain security can be allowed. FDA and industry must remain unyielding in their commitment to the delivery of safe and effective medicines to all Americans.

Overall, GPhA is committed to supporting ongoing FDA supply-chain security initiatives as well as voluntary industry efforts such as Rx–360 and other programs to ensure that all products are safe and effective for the consumer.

Bob Billings is vice-president for policy and interim executive director of the Generic Pharmaceutical Association (GPhA).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here